The FDA approved Roctavian for treating hemophilia A. The regulatory decision makes the BioMarin Pharmaceutical product the first gene therapy for this inherited bleeding disorder.
FDA Approves BioMarin Pharma’s Gene Therapy, the First for Hemophilia A
